Effects of N-acetyl Cysteine During Percutaneous Coronary Intervention

Effects of N-acetyl Cysteine on Periprocedural Myocardial Infarction and Major Cardiac and Cerebral Events in Patients Undergoing Percutaneous Coronary Intervention

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01878669

Acronym

EASE-PCI

Enrollment

390

Registered

2013-06-17

Start date

2013-01-31

Completion date

2026-12-31

Last updated

2025-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

n-acetyl cysteine, percutaneous coronary intervention

Brief summary

The aim of this study is to evaluate the effects of N-acetyl cysteine on periprocedural myocardial infarction and major cardiac and cerebral events in patients undergoing percutaneous coronary intervention and who have moderate to high risk for contrast induced nephropathy.

Interventions

DRUGN-acetyl cysteine

DRUGSaline

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Patients \> 18 years old undergoing percutaneous coronary intervention and who have moderate to high risk for contrast induced nephropathy (Mehran Score ≥ 5)

Exclusion criteria

* Primary percutaneous coronary intervention * Low risk for contrast induced nephropathy (Mehran Score \< 5) * Use of nephrotoxic agents (NSAIDs, aminoglycosides,recent contrast injection...) * Infection * Pregnancy, Lactation * Renal failure requiring dialysis * Hepatic failure * History allergy for NAC * History of Asthma * Chronic nitrate usage * Malignancy * Use of corticosteroids * Leukocytosis,Thrombocytosis,Anemia * Blood pressure of \>180/100mmHg despite anti-hypertensive therapy

Design outcomes

Primary

Measure	Time frame
periprocedural myocardial infarction	postprocedural 3-6 h

Secondary

Measure	Time frame
NAC side effects (Asthma exacerbation, pruritus, dyspnea)	during hospitalization at 48 hours
major cardiac and cerebral events	1 year follow-up

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026